Key insights
- BillionToOne shares declined pre-market after short-seller Fuzzy Panda Research published a report alleging improper billing practices, undisclosed regulatory scrutiny, and questionable clinical claims. The report cites state Medicaid documentation and anonymous former employees, suggesting potential weaknesses in the company's operations. BillionToOne has not yet responded to the allegations, which have not been confirmed by regulatory findings or legal proceedings.

Investing.com -- Shares of molecular diagnostics company BillionToOne, Inc. (NASDAQ: BLLN) fell 6% in pre-market trading Wednesday after short-seller Fuzzy Panda Research published a critical report alleging improper billing practices, undisclosed regulatory scrutiny and potential weaknesses in the company’s clinical claims.
Fuzzy Panda disclosed that it holds a short position in BillionToOne and stands to profit if the stock declines. The report draws on state Freedom of Information Act (FOIA) requests, interviews with anonymous former employees and discussions with physicians. BillionToOne has not publicly responded to the allegations, which have not been established through regulatory findings or court proceedings.
A central focus of the report is Tennessee Medicaid documentation. According to Fuzzy Panda’s interpretation of records obtained from the state, the Office of Program Integrity opened an inquiry in 2024 following 11 tips and referred the matter to the Tennessee Bureau of Investigation’s Medicaid Fraud Control Division. The short seller alleged that the records identified a pattern of inappropriate billing, including the use of miscellaneous "unlisted" CPT codes that it said paid approximately 10 times standard rates.
Fuzzy Panda also questioned why the alleged regulatory scrutiny had not been disclosed in BillionToOne’s securities filings. A referral to a law enforcement agency, however, does not establish that wrongdoing occurred or that formal charges have been filed.
The report separately examined Michigan Medicaid billing data from 2021 through 2026. Fuzzy Panda claimed that BillionToOne billed for once-in-a-lifetime genetic carrier screening alongside approximately 88% of its non-invasive prenatal tests (NIPT). The short seller argued that this rate was unusually high compared with an estimated 40% share of pregnancies involving first-time mothers, and alleged that the company’s sales representatives encouraged bundled testing regardless of medical necessity. It also compared the company’s reported billing patterns with those of competitors Natera and Myriad Genetics.
Another allegation concerns patient cost-sharing. Fuzzy Panda claimed that sales representatives capped patient deductibles and co-pays at between $99 and $349 without verifying income. Anonymous former employees cited in the report characterized the practice as potentially unlawful, raising questions about compliance with federal anti-kickback and physician self-referral restrictions.
Beyond prenatal testing, the report questioned the commercial and clinical positioning of BillionToOne’s Northstar cancer tests. Fuzzy Panda cited interviews with five oncologists who questioned the tests’ differentiation, along with allegations of undisclosed false-negative results in prenatal testing. It also pointed to rising days sales outstanding (DSO) and reimbursement disputes with insurers as potential signs of collection and reimbursement challenges.
Fuzzy Panda’s financial analysis estimated that curbing what it considers excess carrier-screening claims could reduce BillionToOne’s EBITDA by approximately 80%. The short seller also modeled potential nationwide False Claims Act penalties exceeding $1.2 billion, although that figure represents its own hypothetical estimate rather than an established liability.
The report presents a bearish thesis built around reimbursement practices, regulatory exposure and the sustainability of BillionToOne’s revenue. Its allegations and financial estimates have not been independently established, and the company’s response will be important in assessing their significance.
Original Article